73 related articles for article (PubMed ID: 9285564)
1. Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor.
Sheikh MS; Carrier F; Johnson AC; Ogdon SE; Fornace AJ
Oncogene; 1997 Aug; 15(9):1095-101. PubMed ID: 9285564
[TBL] [Abstract][Full Text] [Related]
2. Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells.
Lössner D; Abou-Ajram C; Benge A; Reuning U
Int J Biochem Cell Biol; 2008; 40(12):2746-61. PubMed ID: 18577466
[TBL] [Abstract][Full Text] [Related]
3. Wild-type human p53 activates the human epidermal growth factor receptor promoter.
Deb SP; Muñoz RM; Brown DR; Subler MA; Deb S
Oncogene; 1994 May; 9(5):1341-9. PubMed ID: 8152794
[TBL] [Abstract][Full Text] [Related]
4. A sequence-specific single-stranded DNA-binding protein that is responsive to epidermal growth factor recognizes an S1 nuclease-sensitive region in the epidermal growth factor receptor promoter.
Chen LL; Clawson ML; Bilgrami S; Carmichael G
Cell Growth Differ; 1993 Dec; 4(12):975-83. PubMed ID: 8117624
[TBL] [Abstract][Full Text] [Related]
5. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
6. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
7. Complex regulation of the fibroblast growth factor-binding protein in MDA- MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta.
Kagan BL; Henke RT; Cabal-Manzano R; Stoica GE; Nguyen Q; Wellstein A; Riegel AT
Cancer Res; 2003 Apr; 63(7):1696-705. PubMed ID: 12670924
[TBL] [Abstract][Full Text] [Related]
8. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
Liu J; Zhan M; Hannay JA; Das P; Bolshakov SV; Kotilingam D; Yu D; Lazar AF; Pollock RE; Lev D
Mol Cancer Res; 2006 Nov; 4(11):803-10. PubMed ID: 17077165
[TBL] [Abstract][Full Text] [Related]
9. Identification of two functional estrogen response elements complexed with AP-1-like sites in the human insulin receptor gene promoter.
García-Arencibia M; Dávila N; Campión J; Carmen Carranza M; Calle C
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):1-14. PubMed ID: 15862945
[TBL] [Abstract][Full Text] [Related]
10. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
11. Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation.
Hanafusa T; Shinji T; Shiraha H; Nouso K; Iwasaki Y; Yumoto E; Ono T; Koide N
BMC Cancer; 2005 Jan; 5():9. PubMed ID: 15661074
[TBL] [Abstract][Full Text] [Related]
12. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
13. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
14. The EGF/TGFalpha response element within the TGFalpha promoter consists of a multi-complex regulatory element.
Awwad R; Humphrey LE; Periyasamy B; Scovell W; Li W; Coleman K; Lynch M; Carboni J; Brattain MG; Howell GM
Oncogene; 1999 Oct; 18(43):5923-35. PubMed ID: 10557079
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.
Wang Q; Beck WT
Cancer Res; 1998 Dec; 58(24):5762-9. PubMed ID: 9865734
[TBL] [Abstract][Full Text] [Related]
16. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
17. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the promoter region of the rat neprilysin gene.
Li C; Hersh LB
Arch Biochem Biophys; 1998 Oct; 358(1):189-95. PubMed ID: 9750180
[TBL] [Abstract][Full Text] [Related]
19. p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2004 Aug; 64(15):5078-83. PubMed ID: 15289308
[TBL] [Abstract][Full Text] [Related]
20. Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis.
Zhang L; Kashanchi F; Zhan Q; Zhan S; Brady JN; Fornace AJ; Seth P; Helman LJ
Cancer Res; 1996 Mar; 56(6):1367-73. PubMed ID: 8640827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
